Financing and going-concern dependence
The company may need additional equity or debt to fund R&D, manufacturing, and commercialization.
- Scope
- Corporate funding and operating runway
- Materiality
- high
Profusa, Inc.
Profusa, Inc. is a U.S.-based medical technology company focused on developing and commercializing implantable biosensor products for continuous biochemical monitoring. Its core platform includes the Lumee Oxygen and Lumee Glucose devices, and it also operates through a Singapore subsidiary created to support development and commercialization in Asia Pacific.
0.17
0.17
| % | |
|---|---|
| Implantable biosensors | 70% Core sensor products designed to measure biochemical signals continuously in the body. |
| Glucose monitoring devices | 15% Lumee Glucose products intended for glucose sensing and diabetes-related monitoring. |
| Oxygen monitoring devices | 15% Lumee Oxygen products intended for oxygen sensing and related clinical monitoring. |
Profusa’s customers are primarily healthcare and life-science users that need continuous physiological monitoring,...
- Clinical and healthcare usersprimary
Hospitals, clinicians, and care providers that would use continuous monitoring data for patient management.
- Research and development partnerssecondary
Organizations collaborating on device validation, product development, and clinical evidence generation.
- Commercialization partnersprimary
Third parties that help develop, manufacture, or distribute Lumee products in target markets.
- Asia Pacific joint venture counterpartiessecondary
Regional partners involved in the planned APAC joint venture for development and commercialization.
Profusa is headquartered in the United States and operates through a U.S. parent structure with a wholly owned...
- •Headquartered in the United States
- •Singapore subsidiary supports Asia Pacific expansion
- •APAC structure is intended for regional development and commercialization
- •U.S. operations remain central to corporate and R&D activity
- •Future market access depends on local regulatory and partner execution
Profusa’s strategy centers on advancing Lumee Oxygen and Lumee Glucose through regulatory, manufacturing, and...
01
Regulatory approval and product readinessshort-term
The devices cannot be commercialized at scale without required approvals and validation.
02
Commercialization build-outmedium-term
The company needs manufacturing, sales, and marketing infrastructure to convert development assets into revenue.
03
Asia Pacific partnership executionmedium-term
The Singapore subsidiary and planned joint venture are intended to extend market reach and localize execution.
Profusa faces the typical risks of a development-stage medical device company: regulatory uncertainty, product...
Regulatory approval delays
The Lumee products require approvals before broad commercialization, and delays would push out revenue generation.
- Scope
- Lumee Oxygen and Lumee Glucose
- Materiality
- high
Manufacturing and scale-up execution
Medical device commercialization depends on reliable production, quality control, and supply chain readiness.
- Scope
- Product ramp-up and partner manufacturing
- Materiality
- high
Valuation volatility from complex instruments
Convertible notes, warrant liabilities, and related-party loans are remeasured at fair value.
- Scope
- Earnings and balance sheet volatility
- Materiality
- medium
Warrant liabilities
Non-cash gains or losses in other income/expense
Convertible promissory note valuation
Fair value changes can materially affect reported results
Related-party convertible loan
Quarterly earnings sensitivity to valuation assumptions
Government grant revenue
Comparability across periods is limited
Business combination accounting
Period-to-period comparability and capital structure analysis
: 29.4.2026